Keros Therapeutics drops on halting lung disease trial on safety concerns

Keros Therapeutics

15/01/2025 12:03

** Shares of drug developer Keros Therapeutics  KROS.O  fall
10.26% to $11.20 premarket
    ** Co says it has voluntarily halted all dosing in a
mid-stage trial due to safety concerns
    ** Adds is terminating the trial early, and patients are
expected to be monitored through the end-of-trial visits
    ** The mid-stage trial was studying its experimental drug
cibotercept in combination with background therapy in patients
with pulmonary arterial hypertension, a rare lung condition 
that causes high blood pressure in the pulmonary arteries
    ** Earlier in Dec., co halted the 3.0 mg/kg and 4.5 mg/kg
treatment based on the observation of pericardial effusions,
build up of fluids around the heart, at those dose levels
    ** Co has notified investigators and certain regulatory
authorities, including the FDA, about this decision, and is in
the process of notifying other relevant regulatory authorities
    ** Stock fell ~60% last year

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))